NHI coverage extended to Visudyne, a macular degeneration therpay.

Published: 2005-07-12 06:57:00

Updated: 2005-07-12 06:57:00

Novartis Korea's Visudyne (verteporfin), a photodynamic therapeutic drug for macular degeneration, took the government approval for the NHI coverage effective from July 1, 2005 specifically for 1) the patients suffering from macular degeneration, 2) the patients who showed enlarged and new eye bl...

Fees

- Email service daily and homepage access.

$300 per month. ($3,240 per year)
5 Email holders per each company.
Anual contract base.

Latest News

Which are outstanding tetravalent vaccines even for the young?

Disease treated the most with clinical trial drugs is respiratory disorder like lung cancer

Who will be the next Pharmaceutical Safety Bureau Director?

Celltrion completes clinical trials for Remsima SC for European approval

Sales listed pharmas made in the first half of the year

TOP

BACK